Positions

Overview

  • Dr. Overton joined the UAB faculty in 2011 to assist in the development of the translational research program in the field of vaccinology and to establish a comprehensive hepatitis C program. He serves as the Co-Director of the AVRC and the Clinic Director for the 1917 Hepatitis Clinic. He is Board-certified in Medicine and Infectious Diseases and is licensed to practice in Alabama. His research interests focus on the chronic inflammation and long-term complications of chronic viral infections, specifically HIV and viral hepatitis, as well as understanding the underlying immune system with regards to vaccines and HIV infection. He has published numerous papers on many aspects of the complications of HIV infection. Specifically, he has evaluated vaccine responses among HIV-infected persons in an effort to better characterize the impact of this immunosuppressive state on the development of both humoral and cellular immune responses. He has conducted studies of hepatitis A, hepatitis B, HPV, HIV, anthrax, smallpox, zoster, and influenza vaccines.

    Dr. Overton’s clinical duties include seeing HIV-infected and chronic hepatitis patients in the outpatient setting as well as seeing solid organ and bone marrow transplant patients in the hospital. He has developed strong relationships with the UAB hepatology group as well as the bone marrow transplant unit and can readily identify potential study participants from these high risk populations. In addition, he has considerable experience in performing clinical trials, both randomized controlled trials and observational studies, assessing various parameters related to HIV, HCV, and vaccine responses. He has also served as the lead investigator on several trials within the AIDS Clinical Trial Group.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Brief Report: Aging Attenuates the Association Between Coronary Artery Calcification and Bone Loss Among HIV-Infected Persons 2019
    2019 Rapid boosting of HIV-1 neutralizing antibody responses in humans following a prolonged immunologic rest period 2019
    2019 Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers 2019
    2019 Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) 2019
    2019 Associations of food insecurity and psychosocial measures with diet quality in adults aging with HIV 2019
    2019 Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 2019
    2018 HIV-1 latent reservoir size and diversity are stable following brief treatment interruption 2018
    2018 Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus 2018
    2018 Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status 2018
    2018 Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status. 2018
    2018 The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screening 2018
    2018 Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial 2018
    2018 Reply 2018
    2017 The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus Infection 2017
    2017 Genome-wide admixture and association study of subclinical atherosclerosis in the Women’s Interagency HIV Study (WIHS) 2017
    2017 Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women 2017
    2017 Racial differences in calculated bioavailable Vitamin D with Vitamin D/calcium supplementation 2017
    2017 Examining Sexual Function among Individuals with HIV in a Midwestern US Urban Outpatient Clinic Setting 2017
    2017 The Relationship of Social Support and Neighborhood Perceptions among Individuals with HIV 2017
    2017 Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected women 2017
    2017 Race and sex differences in ambulatory blood pressure measures among HIV+ adults 2017
    2017 Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons 2017
    2017 Local Ancestry and Clinical Cardiovascular Events Among African Americans From the Atherosclerosis Risk in Communities Study 2017
    2017 Admixture Mapping of Subclinical Atherosclerosis and Subsequent Clinical Events among African Americans in 2 Large Cohort Studies 2017
    2017 Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access among African American Men, Women, and MSM in the Deep South 2017
    2017 Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection 2017
    2017 Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation. 2017
    2016 Duration of Influenza Virus Shedding among HIV-Infected Adults in the cART Era, 2010-2011 2016
    2016 Effect of HIV antibody VRC01 on viral rebound after treatment interruption 2016
    2016 Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence 2016
    2016 Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patients 2016
    2016 Psychiatric Diagnoses among an HIV-Infected Outpatient Clinic Population 2016
    2016 Ambulatory blood pressure monitoring in individuals with HIV: A systematic review and meta-analysis 2016
    2016 Incidence and predictors of abnormal anal cytology findings among HIV-infected adults receiving contemporary antiretroviral therapy 2016
    2016 Characterizing failure to establish hepatitis C care of baby boomers diagnosed in the emergency department 2016
    2016 Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: Results of an exploratory substudy of METABOLIK, a phase 4, randomized trial 2016
    2016 High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy 2016
    2016 Low bone mineral density and risk of incident fracture in HIV-infected adults 2016
    2016 The Silent Epidemic - Frailty and Aging with HIV. 2016
    2016 Vitamin D and bone loss in HIV 2016
    2015 Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIV 2015
    2015 Normal T-cell activation in elite controllers with preserved CD4 + T-cell counts 2015
    2015 Obesity is Associated with Race/Sex Disparities in Diabetes and Hypertension Prevalence, but Not Cardiovascular Disease, among HIV-Infected Adults 2015
    2015 Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1 2015
    2015 Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: A cross-sectional pilot study 2015
    2015 Persistent HIV-related stigma among an outpatient US clinic population. 2015
    2015 Preliminary outcomes of a pilot physical therapy program for HIV-infected patients with chronic pain 2015
    2015 A better screening tool for HIV-associated neurocognitive disorders: Is it what clinicians need? 2015
    2015 Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: Effects on endothelial function, lipoproteins, and inflammation 2015
    2015 Impact of poor retention in HIV medical care on hepatitis B vaccination 2015
    2015 Inhibition of the lymphocyte metabolic switch by the oxidative burst of human neutrophils 2015
    2015 Parks as a tool for HIV management 2015
    2015 Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: An open-label, controlled clinical phase II trial 2015
    2015 Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department 2015
    2015 Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A Randomized Trial 2015
    2014 National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States 2014
    2014 Improving cervical cancer screening rates in an urban HIV clinic 2014
    2014 Bone alterations associated with HIV 2014
    2014 Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans 2014
    2014 Depression severity is associated with increased risk behaviors and decreased CD4 cell counts 2014
    2014 Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort 2014
    2014 Beliefs, experience, and interest in pharmacotherapy among smokers with HIV 2014
    2014 Metabolic consequences of HIV: Pathogenic insights 2014
    2014 Bones, fractures, antiretroviral therapy and HIV topical collection on HIV/AIDS 2014
    2014 Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care 2014
    2014 Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients 2014
    2014 Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults. 2014
    2014 HIV-Related Metabolic Comorbidities in the Current ART Era 2014
    2014 Metabolic complications of HIV infection and its therapies 2014
    2013 Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale 2013
    2013 Are neighborhood conditions associated with HIV management? 2013
    2013 Relationships among HIV infection, metabolic risk factors, and left ventricular structure and function 2013
    2013 Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death 2013
    2013 Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviraltreated HIV-infected adults in the US 2013
    2013 Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care 2013
    2013 Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia ankara as a smallpox vaccine in HIV-infected subjects 2013
    2013 The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons 2013
    2013 Pain is independently associated with impaired physical function in HIV-infected patients 2013
    2013 Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in hiv-positive individuals with metabolic complications 2013
    2012 Screening anxiety in the HIV clinic 2012
    2012 Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero 2012
    2012 Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks 2012
    2012 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors 2012
    2012 Urban farming: A non-traditional intervention for HIV-related distress 2012
    2012 Sometimes, more is better 2012
    2012 Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy 2012
    2012 Cystatin C and baseline renal function among HIV-infected persons in the SUN study 2012
    2012 Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the united states 2012
    2012 Reply to Ganesan et al 2012
    2012 Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans 2012
    2012 A Review of Opioid Prescribing Practices and Associations with Repeat Opioid Prescriptions in a Contemporary Outpatient HIV Clinic 2012
    2012 Effect of darunavir on lipid profile in HIV-infected patients 2012
    2012 Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: Implications for prevention interventions 2012
    2012 Serostatus disclosure among adults with HIV in the era of HIV therapy 2012
    2011 Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis 2011
    2011 Performances on the cogstate and standard neuropsychological batteries among HIV patients without dementia 2011
    2011 Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort 2011
    2011 A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging 2011
    2011 Increasing clarity on bone loss associated with antiretroviral initiation 2011
    2011 Erratum: High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy (Clinical Infectious Diseases (2011) 52 (378-386)) 2011
    2011 Factors associated with non-adherence to antiretroviral therapy in the SUN study 2011
    2011 Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals 2011
    2011 Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (The SUN Study) 2011
    2011 High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy 2011
    2011 Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population 2011
    2011 The rapidly evolving research on vitamin D among HIV-infected populations 2011
    2011 Alcohol consumption is associated with poor health in HIV clinic patient population: A behavioral surveillance study 2011
    2011 Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity 2011
    2011 GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. 2011
    2011 Perceptions of alcohol risk among individuals living with HIV 2011
    2011 STD/HIV risk among adults in the primary care setting: Are we adequately addressing our patients'needs? 2011
    2010 Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States 2010
    2010 Bone disease in HIV infection: A practical review and recommendations for HIV care providers 2010
    2010 Do brief screening questions or provider perception accurately identify persons with low health literacy in the HIV primary care setting? 2010
    2010 Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommon 2010
    2010 Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220 2010
    2010 Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors 2010
    2010 Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection 2010
    2010 The interplay of sociodemographic factors on virologic suppression among a U.S. outpatient HIV clinic population 2010
    2010 Sexual behaviors and results of bacterial sexually transmitted infections testing among frail HIV-infected individuals 2010
    2010 Aging and HIV infection: A comparison between older HIV-infected persons and the general population 2010
    2010 Renal and Urologic Emergencies in the HIV-infected Patient 2010
    2010 The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy. 2010
    2009 A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV 2009
    2009 Frailty among HIV-infected persons in an urban outpatient care setting 2009
    2009 Routine screening for depression: Identifying a challenge for successful HIV care 2009
    2009 Can you hear me now? Limited use of technology among an urban HIV-infected cohort 2009
    2009 Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome 2009
    2009 Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy 2009
    2009 The study to understand the natural history of HIV and AIDS in the Era of effective therapy (SUN study) 2009
    2009 HIV and aging: two converging epidemics. 2009
    2008 Adverse effects of tenofovir use in HIV-infected pregnant women and their infants 2008
    2008 Effect of postpartum HIV treatment discontinuation on long-term maternal outcome 2008
    2008 Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraception 2008
    2008 The aging of the HIV epidemic 2008
    2008 Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals 2008
    2007 An overview of vaccinations in HIV 2007
    2007 Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women 2007
    2007 FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection 2007
    2007 Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individuals 2007
    2007 Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population 2007
    2007 Predictors of immunity after hepatitis a vaccination in HIV-infected persons 2007
    2007 Factors associated with seronegative chronic hepatitis C virus infection in HIV infection 2007
    2006 Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic 2006
    2006 Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy 2006
    2005 Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis 2005
    2005 Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons 2005
    2005 Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy 2005

    Chapter

    Year Title Altmetric
    2013 Infections of the immunocompromised patient.  704-709. 2013
    2012 Infections of the immunocompromised patient.  704-709. 2012
    2012 Prevention of hepatitis infection in HIV-Infected patients.  151-161. 2012

    Principal Investigator On

  • Private Grant  awarded by GlaxoSmithKline 2014 - 2022
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2022
  • Private Grant  awarded by BAVARIAN NORDIC A/S 2019 - 2021
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2021
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2021
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2021
  • Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)  awarded by University of Colorado 2016 - 2021
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2017 - 2020
  • HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men  awarded by FAMILY HEALTH INTERNATIONAL 2017 - 2020
  • Private Grant  awarded by GlaxoSmithKline 2019 - 2020
  • Private Grant  awarded by Gilead Sciences 2019 - 2020
  • Effect of Pitavastatin on Kidney Function in HIV-infected Persons  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2020
  • Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2020
  • Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332) and ACTG A6333s The Mechanistic Substudy of REPRIEVE  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2020
  • Cardiovascular Disease Risk in HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial Participants  awarded by Brigham and Women's Hospital 2016 - 2020
  • ACTG Protocol Funds  awarded by University of California, Los Angeles 2018 - 2019
  • Leadership And Operations Center (LOC), AIDS Clinical Trials Group (ACT6) [UM1AI068636]-A5332 Committee Chair Support  awarded by University of California, Los Angeles 2018 - 2019
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) (UM1A068636-13)  awarded by University of California, Los Angeles 2018 - 2019
  • AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support  awarded by Brigham and Women's Hospital 2015 - 2019
  • Evaluating Nonavalent HPV Vaccine Immunogenicity among Adult Renal Transplant Recipients (Fixed Price Agreement)  awarded by Northwestern University 2016 - 2019
  • Evaluating Nonavalent HPV vaccine Immunogenicity among Adult Renal Transplant Recipients  awarded by Northwestern University 2016 - 2019
  • High VS. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients  awarded by VANDERBILT UNIVERSITY 2017 - 2019
  • A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)  awarded by University of California, Los Angeles 2018 - 2019
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding  awarded by Brigham and Women's Hospital 2014 - 2018
  • Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee  awarded by Brigham and Women's Hospital 2014 - 2018
  • AIDS Clinical Trials Group: Protocol Funds  awarded by Brigham and Women's Hospital 2014 - 2018
  • A5361s: Pitvastatin to Reduce Physical Function Impairment and Frailty in HIV  awarded by Brigham and Women's Hospital 2016 - 2018
  • Private Grant  awarded by Gilead Sciences 2012 - 2017
  • Private Grant  awarded by Gilead Sciences 2012 - 2017
  • HPTN 083 A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender  awarded by FAMILY HEALTH INTERNATIONAL 2016 - 2017
  • Private Grant  awarded by BAVARIAN NORDIC A/S 2014 - 2017
  • Effect of Low Dose Methotrexate on Endothelial Function and Inflammation in HIV - A5314  awarded by Brigham and Women's Hospital 2013 - 2017
  • Private Grant  awarded by Gilead Sciences 2012 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2015
  • Private Grant  awarded by BAVARIAN NORDIC A/S 2013 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2014
  • UAB Center for AIDS Research - The Detrimental Nexus of HCV and HIV Infection on Bioenergetics and Immune Function  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • Private Grant  awarded by Gilead Sciences 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by Brigham and Women's Hospital 2012 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013
  • Private Grant  awarded by ABBVIE INC 2013
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2011 - 2013
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by SOCIAL & SCIENTIFIC SYSTEMS 2011 - 2012
  • Investigator On

  • UAB Center for AIDS Research (CFAR)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2019 - 2024
  • UAB Center for AIDS Research - Core C - Clinical Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2019 - 2024
  • VVTEU Protocol Development and Implementation for Task Areas B-C Phase II Vaccine Trial for Influenza (“Flu Pandemic” or “H7”)  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER 2014 - 2023
  • Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER 2014 - 2023
  • Vaccine and Treatment Evaluation Units - Admin Task  awarded by VANDERBILT UNIVERSITY 2014 - 2023
  • UAB Institutional Career Development Program in HIV-Related Heart, Lung, Blood and Research  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by Gilead Sciences 2018 - 2022
  • Private Grant  awarded by PROTEUS DIGITAL HEALTH, INC. 2017 - 2022
  • Unsolicited R24 CFAR Network of Clinical Systems (CNICS)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2016 - 2021
  • HVTN 703/HPTN 081 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2015 - 2020
  • The Guts of HIV: Innate Immune Dysregulation as a Central Mechanism of Gastrointestinal and Liver Disease in HIV-1-Infected Individuals  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2020
  • Neutrophil Dysregulation as a Driving Mechanism of Cardiovascular Disease in HIV-1-Infection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2020
  • Private Grant  awarded by GENECURE BIOTECHNOLOGIES, LLC 2015 - 2020
  • Private Grant  awarded by Gilead Sciences 2016 - 2020
  • Clincial Research Site Activities for the LTE to HVTN 117/HPX2004  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2019
  • HVTN 704/HPTN 085 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2019
  • HVTN Protocol Funding Year 13  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2019
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 118/HPX2003 - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2019
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • COMPLETED - SPORE in Cervical Cancer - Project 3  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University 2014 - 2019
  • HPTN 078: Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States  awarded by FAMILY HEALTH INTERNATIONAL 2015 - 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - Clinical Core C  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - Lipidomic Profiling in HIV Patients Newly Initiating Antiretroviral Treatment  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - The Microbiome, Diet, and Incomplete CD4 Recovery on Antiretroviral Therapy  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - The Role of HIV-Infection and Antiretroviral Therapy Related Mitochondrial Toxicity in Accelerated Aging  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • Private Grant  awarded by GlaxoSmithKline 2012 - 2019
  • Private Grant  awarded by Gilead Sciences 2016 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Stimulate Research in HIV/AIDS Cancer Research  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by JANSSEN R&D IRELAND 2016 - 2019
  • HVTN 704/HPTN 085 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2016 - 2018
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2015 - 2018
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 117/118  awarded by Hutchinson (Fred) Cancer Research Center 2015 - 2018
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2016 - 2018
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2017 - 2018
  • Private Grant  awarded by VICAL, INC. 2017 - 2018
  • Private Grant  awarded by MERCK & COMPANY, INC. 2015 - 2018
  • Private Grant  awarded by Gilead Sciences 2014 - 2018
  • Private Grant  awarded by Gilead Sciences 2015 - 2018
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2013 - 2017
  • Private Grant  awarded by ABBVIE INC 2013 - 2017
  • Private Grant  awarded by MERCK & COMPANY, INC. 2014 - 2017
  • Private Grant  awarded by Gilead Sciences 2015 - 2017
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2015 - 2017
  • Private Grant  awarded by Gilead Sciences 2013 - 2017
  • Private Grant  awarded by Gilead Sciences 2013 - 2017
  • UAB-MISS WIHS Cohort  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2013 - 2016
  • Screening, Evaluation, and Treatment of Anal Intraepithelial Neoplasia  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2014 - 2016
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2015 - 2016
  • Private Grant  awarded by CEPHEID 2015 - 2016
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2016
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2014 - 2016
  • Private Grant  awarded by Gilead Sciences 2013 - 2016
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2016
  • Private Grant  awarded by HEMISPHERX BIOPHARMA, INC. 2012 - 2016
  • Private Grant  awarded by VICAL, INC. 2014 - 2016
  • Private Grant  awarded by Gilead Sciences 2013 - 2016
  • Private Grant  awarded by GlaxoSmithKline 2015
  • HVTN 703/HPTN 081 Site Readiness  awarded by Hutchinson (Fred) Cancer Research Center 2015
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2014 - 2015
  • Private Grant  awarded by MERCK & COMPANY, INC. 2014 - 2015
  • Regional AIDS Education and Training Centers-Base  awarded by Emory University 2014 - 2015
  • Private Grant  awarded by Gilead Sciences 2013 - 2015
  • Population Genetics Analysis Program: Immunity to Vaccines/Infections II  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2012 - 2015
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2014 - 2015
  • Private Grant  awarded by Gilead Sciences 2014 - 2015
  • Private Grant  awarded by Gilead Sciences 2010 - 2015
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2014
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2012 - 2014
  • Private Grant  awarded by ABBVIE INC 2013 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2011 - 2014
  • Private Grant  awarded by Gilead Sciences 2012 - 2014
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • Private Grant  awarded by Gilead Sciences 2012 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2014
  • Private Grant  awarded by Genentech 2012 - 2014
  • HVTN 505 Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center 2010 - 2013
  • HVTN Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center 2010 - 2013
  • Private Grant  awarded by Gilead Sciences 2012 - 2013
  • Alabama - Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2007 - 2013
  • Private Grant  awarded by Gilead Sciences 2013
  • Private Grant  awarded by Gilead Sciences 2012 - 2013
  • Private Grant  awarded by Gilead Sciences 2012 - 2013
  • Education And Training

  • UAB Hospital, Internship 2000
  • UAB Hospital, Residency 2002
  • Barnes-Jewish West County Hospital, Postdoctoral Fellowship 2004
  • Full Name

  • Edgar Overton